<< Вернуться к списку статей журнала

Том 2 №3 2000 год - Нефрология и диализ

Ятрогенная гиперкалиемия: диагностика и лечение

Костас С. Сиамопулос Мозес Элисаф Костас Катоподис

Аннотация: Гиперкалиемия является угрожающим жизни электролитным нарушением. В обычных условиях она наблюдается редко, благодаря гомеостатическим механизмам, обеспечивающим поддержание нормального уровня калия в плазме крови. Среди этих механизмов особое место занимает способность почек усиленно экскретировать калий при повышении его уровня в крови. Следовательно, гиперкалиемия почти всегда связана с повреждением этого механизма. Однако при острой и хронической почечной недостаточности ее развитию может способствовать и избыточное поступление калия извне. ** Публикуется по согласованию с автором и с разрешения Oxford University Press. ** Перевод И.Г. Ким

Для цитирования: Костас С. Сиамопулос, Мозес Элисаф, Костас Катоподис Ятрогенная гиперкалиемия: диагностика и лечение. Нефрология и диализ. 2000. 2(3):176-181. doi:

Весь текст

Список литературы:

1. Brown R.S. Extrarenal potassium homeostasis. Kidney Int 1986; 30: 116-127.
2. Stanton B.A. Renal potassium transport: Morphological and functional adaptations. Am J Physiol 1989; 257: R989-R997.
3. Wright F.S. Renal potassium handling. Semin Nephrol 1987; 7: 174-184.
4. Rabelink T.J., Koomans Н.А., Hene’ R.J., Dorhout Mees E.J. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38: 942-947.
5. Rose B.D. Hyperkalemia In: Rose B.D., ed. Clinical Physiology of Acid-Base and Electrolyte Disorders, 4th edn. McGraw Hill, New York, 1994; 823-862.
6. Ponce S.P., Jennings A.E., Madias N.E., Harrington J.T. Drug-induced hyperkalemia. Medicine 1985; 64: 357-370.
7. DeVita M.V., Han H., Chan R., Zabetakis P.M., Gleim G.W., Michelis M.F. Drug use and the elderly in relation to changing etiologies of hyperkalemia. Geriatr Nephrol Urol 1991; 1: 41-45.
8. Rimmer J.M., Horm J.F., Gennari F.J. Hyperkalemia as a complication of drug therapy. Arch Intern Med 1987; 147: 867-869.
9. Michelis M.F. Hyperkalemia in the elderly. Am J Kidney Dis 1990; 16; 296-299.
10. Hegstad R., Brown R.D., Jiang N.-S. et al. Aging and aldosterone. Am J Med 1983; 74: 442-448.
11. Mulkerrin E., Epstein F.H., Clark B.A. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol 1995; 6: 1459-1462.
12. DuBose T.D. Hyperkalemic hyperchloremic metabolic acidosis: pathophysiologic insights. Kidney Int 1997; 51: 591-602.
13. Alappan R., Perazella M.A., Buller G.K. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124: 316-320.
14. Elisaf M., Terrovitou Ch., Tomos P., Siamopoulos К.С. Severe hyperkalaemia after co-trimoxazole administration in a patient with hyporeninaemic hypoaldosteronism. Nephrol Dial Transplant 1997; 12: 1254-1255.
15. DcFronzo R.A. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17: 118-114.
16. Williams G.H. Hyporeninemic hypoaldosleronism. N Engl J Med 1986; 314; 1041-1042.
17. Choi M.J, Fernandez P.C, Patnaik A. et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N EngI J Med 1993; 328: 703-706.
18. Velazquez H., Perazella M.A., Wright F.S., Ellison D.H. Renal mechanism of trimethoprim-incluced hyperkalemia. Ann Intern Med 1993; 119: 296-301.
19. Schreiber M., Schlanger L.E., Chcn C.-B. et al. Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int 1996; 49: 82-87.
20. Schreiber M., Halperin M.L. Urea excretion rate as a contributor to trimethoprim-induced hyperkalemia. Aim Intern Med 1994; 120: 166-167.
21. Reiser I.W., Chou S.-Y., Brown M.I., Porush J.G. Reversal of trimethoprim-induced antikaliuresis. Kidney Int 1996; 50: 2063-2069.
22. Zager R.A. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Jnt 1996; 49: 314-326.
23. Prendergast B.D., George C.F. Drug-induced rhabdomyolysis mechanisms and management. Postgrad Med J 1993; 69: 333-336.
24. Terrovitou C.T., Milionis H.J., Elisaf M.S. Acute rhabdomyolysis after bezafibrate re-exposure. Nephron (in press).
25. Demedts W., Desager Z., Belpaire F., Rinqon S., Lameire N. Life threatening hyperkalemia associated with clofibrale-induced myopathy in a CAPD patient. Perit Dial Bull 1983: 3: 15-16.
26. Textror S.C., Bravo E.L., Fouad F.M., Tarazi R.C. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril Am J Med 1982; 73:719-725.
27. Doman К., Pcrlmuttcr J.A., Muhamincdi M. et al. Life-threatening hyperkalemia associated with captopril administration. South Med J 1993; 86: 1269-1272.
28. Gorriz J.L., Garcia-Ramos J.L., Pallardo L.M. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 1995; 10: 2371-2372.
29. Chan MK. Sustained-release bezafibrate соrrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 56-61.
30. Van Puijenbroek E.P., DuBuf-Vcreijken P.W.G., Spooren P.F.M.J., Van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403-404.
31. Panuccio V., Enia G., Parlongo S., Cutrupi S., Zoccali C. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient. Nephron 1996; 73: 736.
32. Bcdani P.L., Perini L., Gilli P. Acute rhahdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron 1994: 68: 512-513.
33. Gupta P., Franco-Saenz R., Mulrow P.J. Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin and potassium stimulated aldosterone secretion. Hypertension 1995; 25: 443-448.
34. Pratt J. Role of angiotensin II in potassium mediated aldosterone secretion in the dog. J Clin Invest 1982: 70: 667-672.
35. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med 1984: 144: 1947-1953.
36. Grossman A., Eckland D., Price P. et al. Captoprii: reversible renal failure with severe hyperkalemia. Lancet 1980: 1: 712.
37. Packer M., Lee W.H. Provocation of’ hyper- and hypokalemic sudden death during treatment with and withdrawal of converting enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol 1986; 57: 347-370.
38. Burnakis T.G., Mioduch H.J. Combined therapy with captopril and potassium supplementation. Arch lntern Med 1984: 144: 2371-2372.
39. Sterns R.H., Spital A. Disorders of internal potassium balance. Semin Nephrol 1987; 7: 206-222.
40. BauerJ.H. Effects of propranolol therapy on renal function and body fluid composition. Arch Intern Med 1983; 14: 927-931.
41. Lim M., Lipton R.A.F., Wolff C.B., Band D.M. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 12: 591.
42. Belhune D., McKay R. Paradoxical changes in serum-potassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet 1978; 12: 380-381.
43. Lowenthal D.T., Affrime M.B., Rosenthal L., Gould A.B., Borruso J., Falkner B. Dynamic and biochemical responses to single and repeated doses clonidine during dynamic physical activity. Clin Pharmacol Ther 1982; 32: 18-24.
44. Rosenihal L.S., Lowenthal D.T., Affrime M.B., Falkner B., Gould A.B. The renin-aldosterone-potassium response to methyldopa during dynamic physical activity. Clin Phurniacul Ther 1982; 31: 264-265.
45. Castellino P., Bia M.J., DeFronzo R.A. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37: 773-798.
46. Tan S.Y., Shapiro R., Franco R. et al. Indomethacin induced prostaglandin inhibition with hyperkalemia; A reversible cause of hyporeninic hypoaldosteronism. Ann Intern Med 1979; 90: 783-785.
47. Garella S., Matarese R.A. Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine 1984; 3:165-181.
48. Zimran A., Kramer M., Plaskin M., Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Lancet 1985; 291: 107-108.
49. Phelps K.R., Oh M.S., Carroll H.J. Heparin-induced hyperkalemia. Report of a case Nephron 1980; 25: 254.
50. Sherman R.A., Ruddy M.C. Suppression of aldosterone production by low-dose heparin. Am J Nephrol 1986; 6: 165.
51. О’Kelly R., Magee F., McKenna T.F. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 1983; 56: 108-112.
52. Edes Т.Е., Sunderrajan E.V. Heparin-induced hyperkalemia. Arch Intern Med 1985; 145: 1070-1072.
53. Oster J.R., Singer I., Fishman L.M. Heparin-induced aldosterone suppresion and hyperkalemia. Am J Med 1995; 98: 575-586.
54. Gonzalez-Martin G., Diaz-Molinas M.S., Martinez A.M. et al. Heparin-induced hyperkalemia: a prospective study. Inl J Clin Pharmacol Ther Toxicol 1991; 29: 446-450.
55. Durand D., Ader J.-L., Rey J.-P. et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int1988; 34 [Suppl25]: S196-S197.
56. Antonipillai I., Wang Y., Horton R. Tumor necrosis factor and inlerleukin-1 may regulate renin secretion. Endocrinology 1990; 126: 273-278.
57. Canova C.R., Fischler M.P., Reinhart W.H. Effect of low-molecular-wcight heparin on serum potassium. Lancet 1997; 349: 1447-1448.
58. Wiggam M.I., Beringer T.R.O. Effect of low-molccular-weight heparin on serum concentrations of potassium. Lancet 1997; 350: 292-293.
59. Kleyman T.R., Robers С., Ling B.N. A mechanism for pentamid-ine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122: 103-106.
60. Kalin M., Poretsky L., Seres D.J., Zumoff B. Hypereninemic hypoaldosteronism associated with AIDS. Am J Med 1987; 82: 1035-1038.
61. Kamel K.S., Ethier J.H., Quaggin S. et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1991; 2: 1279-1284.
62. Bantle J.P., Nath K.A., Sutherland E.R., Najarian J.S., Ferns T.F. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med 1985; 145: 505-508.
63. Smith T.W. Digitalis: Mechanisms of action and clinical use. N Engl J Med 1988; 318: 358-365.
64. Lown B., Black A., Moore F.D. Digitalis, electrolytes and the surgical patient. Am J Cardiol 1960; 6: 309-311.
65. Asplund J., Edhag О., Mogensen L. et al. Four cases of massive digitalis poisoning. Acta Med Scand 1971; 189: 293-297.
66. Reza M.J., Kovick R.B., Shine K.I., Pearce M.L. Massive intravenous digoxin overdosage. N Engi J Med 1974; 291: 777-778.